Beacon Therapeutics Funding: $290M Raised, Series B (2024)
Beacon Therapeutics is based in London, England. It has raised $290M in total funding. Latest round: Series B.
Beacon Therapeutics funding overview
Beacon Therapeutics is based in London, England. Beacon Therapeutics has raised $290M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series B announced in July 2024. The round record for Beacon Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Forbion, Syncona, Oxford Science Enterprises, TCGX, Advent Life Sciences. 5 distinct backers are named across the disclosed rounds.
Beacon Therapeutics at a glance
Total raised
$290M
Latest round
Series B
Latest round date
July 2024
Headquarters
London, England
Notable investors
Forbion, Syncona, Oxford Science Enterprises, TCGX, Advent Life Sciences
Frequently asked about Beacon Therapeutics funding
How much has Beacon Therapeutics raised?
Beacon Therapeutics has raised $290M in total disclosed funding across the rounds on record.
Who has invested in Beacon Therapeutics?
Forbion, Syncona, Oxford Science Enterprises, TCGX, Advent Life Sciences are named among the investors backing Beacon Therapeutics.
What was the latest Beacon Therapeutics funding round?
The most recent disclosed round is a Series B, announced in July 2024.
Where is Beacon Therapeutics based?
Beacon Therapeutics is based in London, England.
When did Beacon Therapeutics last raise?
The last disclosed Beacon Therapeutics round closed in July 2024 at Series B.
We update the Beacon Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in London and their backers are listed below.
